Price
$50.57-0.86%Social Signal Score
Analyst Ratings
9 analysts52-week range
- Last close
- $50.57
- Off 52w high
- -4.8%
- 200-day average
- $46.41
- vs 200-day
- +9.0%
Revenue
$6.68B+189.06%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Eric Slifka
- Sector
- Energy
- Industry
- Oil & Gas Midstream
- Employees
- 4,700
- Beta
- 1.09
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 6.13
Financials
Revenue
$6.68B+189.1%Net Income
$46.45MEBITDA
$120.77MFree Cash Flow
$137.89MEPS (diluted)
$1.26Shares Outstanding (diluted)
34.13M+1.8%Operating Expenses
$79.35MCash & Debt
$21.55MReturn of Capital
$34.78MRevenue by Segment (annual)
$18.56BDividend per Share
$0.79Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $18.56B | $79.22M | $2.13 |
| 2024 | $17.16B | $107.69M | $2.45 |
| 2023 | $16.49B | $152.51M | $3.77 |
| 2022 | $18.88B | $362.21M | $10.06 |
| 2021 | $13.25B | $60.80M | $1.79 |
| 2020 | $8.32B | $102.21M | $2.77 |
| 2019 | $13.08B | $35.87M | $0.82 |
| 2018 | $12.67B | $103.91M | $3.08 |
| 2017 | $8.92B | $58.75M | $1.74 |
| 2016 | $8.24B | $-199.41M | $-5.95 |
| 2015 | $10.31B | $43.56M | $1.12 |
| 2014 | $17.27B | $114.71M | $3.97 |
| 2013 | $19.59B | $42.62M | $1.43 |
| 2012 | $17.63B | $46.74M | $1.73 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from GLP's reported EPS growth of 1.6% a year over 13 years.
- EPS in 5 years
- $2.53
- Implied price
- $50.64
- Return from $42.13
- 3.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $25.18 — -40.2% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 14 | 17 | 20 | 23 | 26 |
|---|---|---|---|---|---|
| -8.4% | -12.9% | -9.5% | -6.5% | -3.8% | -1.4% |
| -3.4% | -8.1% | -4.5% | -1.4% | 1.4% | 4.0% |
| 1.6% | -3.4% | 0.4% | 3.7% | 6.7% | 9.3% |
| 6.6% | 1.4% | 5.4% | 8.9% | 11.9% | 14.7% |
| 11.6% | 6.1% | 10.3% | 14.0% | 17.2% | 20.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
30-40.00%Social Signal Score
Mentions (92)
- Newscnbc.com·14h ago·Negative
Pizza chains are under pressure. GLP-1 use is only one part of the problem Big pizza chains such as Domino's, Papa Johns and Pizza Hut are under pressure as value-conscious diners choose from more delivery choices and changing eating habits reshape demand. Thousands of U.S. pizza locations have permanently shuttered since the category's peak in 2019.
View source ↗ - Newsthenewswire.com·3d ago·Neutral
Lexaria's Human Study GLP-1-H26-7 Completes Dosing as Scheduled Kelowna, BC – November 19, 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, reports that final dosing has been completed on schedule with Human Pilot Study #7 (GLP-1-H26-7) that is evaluating two oral DehydraTECH-semaglutide (“DHT-sema”) compositions against Novo's® (“Novo”) commercially available Wegovy® tablets, over a 5-week duration (the “Stu…
View source ↗ - Newsglobenewswire.com·5d ago·Neutral
Teladoc Health Expands Comprehensive Weight Care Program with Employer Contribution Option for GLP-1 Medications Teladoc Health's new offering gives employers greater flexibility to offer GLP-1 coverage and high-quality care that fits the needs of their workforce
View source ↗ - Newsglobenewswire.com·6d ago·Neutral
Omada Health Presents AI-Powered Meal Feedback Research and 12-Month GLP-1 Care Track Outcomes at ObesityWeek 2026 Omada's AI-powered Meal Map tool, built to focus on nutrient quality rather than restrictive eating, helped members build meal-tracking habits linked to greater weight loss at week 16. In Omada's GLP-1 Care Track, 71% of members stayed on their medication for a full year, and those who did lost 18.4% of body weight, comparable to clinical trials.
View source ↗ - Newsnypost.com·7d ago·Positive
CVS says GLP-1s save money when priced below $350 per month The analysis looked at patients who were newly taking highly popular GLP-1 medicines — which mimic the GLP-1 hormone and reduce appetite — from Eli Lilly and Novo Nordisk, and compared them to similar patients who were not taking the drugs.
View source ↗ - Newsseekingalpha.com·12d ago·Negative
Hims & Hers Health: Don't Nitpick Quarterly Results Hims & Hers Health maintains robust growth prospects despite a minor Q3'26 revenue miss, leading to a market overreaction. HIMS strategically reduced marketing spend to prepare for the Eli Lilly GLP-1 partnership, international brand consolidation, and upcoming peptide product launch. Gross margins slipped to 57% due to Eucalyptus integration, though margins are likely to remain lower due to branded GLP-1 deals.
View source ↗ - Newsfool.com·12d ago·Negative
Eli Lilly vs Novo Nordisk: What's the Better GLP-1 Stock to Buy? Eli Lilly has been generating incredible growth in recent quarters due to its top GLP-1 drugs. Novo Nordisk has struggled due to sluggish numbers, but a higher-dose version of Wegovy could change that.
View source ↗ - Newsglobenewswire.com·12d ago·Neutral
Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek® 2026 SAN CARLOS, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company focused on diabetes and obesity, today announced that it will present Phase 1 clinical results for BMF-650, its investigational next-generation oral small molecule GLP-1 receptor …
View source ↗ - Newscnbc.com·12d ago·Negative
FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound The FDA is requiring the makers of all GLP-1 medications to add a warning about the potential increased risk of NAION. NAION is a rare condition caused by decreased blood flow to the front part of the optic nerve and can result in sudden decreased vision, including permanent vision loss.
View source ↗ - News247wallst.com·13d ago·Negative
Eli Lilly May Have Just Found a New $23 Billion Market for Its GLP-1 Pill Eli Lilly (NYSE:LLY | LLY Price Prediction) just gave its newest drug a second act.
View source ↗ - Newszacks.com·13d ago·Neutral
Here's Why Global Partners (GLP) Is a Great 'Buy the Bottom' Stock Now Global Partners (GLP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
View source ↗ - Newsglobenewswire.com·13d ago·Negative
Zealand Pharma announces Boehringer Ingelheim's survodutide is the first glucagon/GLP-1 dual agonist to demonstrate a favorable cardiovascular safety profile in global Phase 3 SYNCHRONIZE-CVOT trial with significant cardiometabolic benefits Company announcement – No. 55 / 2026 Zealand Pharma announces Boehringer Ingelheim's survodutide is the first glucagon/GLP-1 dual agonist to demonstrate a favorable cardiovascular safety profile in global Phase 3 SYNCHRONIZE-CVOT trial with significant cardio…
View source ↗ - Newsprnewswire.com·14d ago·Negative
Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications – HARMONY IN DIVERSITY is the first study of combined neurotoxin and filler treatment in adults on glucagon-like peptide-1 (GLP-1) medications. In this Phase 4 cohort, participants reported statistically significant improvements in satisfaction with facial appearance and skin quality following a treatment regimen that also included skincare – Inte…
View source ↗ - Newsmarketbeat.com·15d ago·Positive
What Global Partners (GLP) Said on Its Q3 Earnings Call Global Partners NYSE: GLP reported higher third-quarter earnings as stronger wholesale margins more than offset lower retail fuel volumes, which executives attributed to higher pump prices.
View source ↗ - Newsseekingalpha.com·16d ago·Positive
Global Partners LP Common Units (GLP) Q3 2026 Earnings Call Transcript Global Partners LP Common Units (GLP) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketwatch.com·16d ago·Positive
Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying. As part of the agreement, Hims said it won't compound GLP-1 medications like Zepbound in the future.
View source ↗ - Newszacks.com·17d ago·Neutral
Is Global Partners (GLP) a Solid Growth Stock? 3 Reasons to Think "Yes" Global Partners (GLP) could produce exceptional returns because of its solid growth attributes.
View source ↗ - Newsreuters.com·18d ago·Negative
GLP-1 drugs help control prediabetes better than current standard medicine Today we feature a trio of interesting studies that will be presented in detail at the American Heart Association scientific sessions in Chicago this weekend.
View source ↗ - Newsetftrends.com·19d ago·Neutral
What the Holidays Hold for GLP-1 Stocks in THNR The holiday season is almost here and will soon be followed by the annual surge in New Year's resolutions. This will likely drive renewed interest in GLP-1 products, especially as new oral GLP-1 pills hit the market just in time.
View source ↗ - Newsfool.com·21d ago·Neutral
Novo Nordisk Trades at 10 Times Earnings While Buying Back Billions in Stock. Is This the Bottom? Novo Nordisk is one of two leading GLP-1 producers. The company is cutting prices on its GLP-1 drugs as it shifts toward a volume-driven model.
View source ↗ - Newsglobenewswire.com·24d ago·Neutral
Fractyl Health Announces Market Research Highlighting Substantial Patient Interest in a One-Time Procedural Approach to Post-GLP-1 Weight Maintenance Company estimates approximately one million U.S. patients each month discontinue GLP-1 medications and face the risk of weight regain One-third of surveyed GLP-1 users expressed a preference for an endoscopic procedure over continued GLP-1 medication A one-time procedure and freedom from daily or weekly medication were the most frequently selected …
View source ↗ - Newsbenzinga.com·26d ago·Neutral
Vanda Pharmaceuticals Targets Major GLP-1 Market Challenge with Positive Trial Outcomes Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) released results from its Phase 3 trial evaluating Nereus, an oral therapy aimed at preventing vomiting associated with GLP-1 receptor agonist treatments.
View source ↗ - Newsprnewswire.com·26d ago·Negative
Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced Vomiting NEREUS™ significantly reduced semaglutide induced vomiting including frequent multi-day and extreme vomiting Key Results Any vomiting (primary) 43.0% (61/142) vs 58.5% (96/164) placebo (p=0.006); 27% relative reduction Vomiting + severe nausea (key secondary): 33.1% (47/142) vs 50.6% (83/164) (p=0.002); 35% relative reduction Frequent multi-day vomiting (>2 episodes …
View source ↗ - Newsetftrends.com·31d ago·Negative
What Is the Peptide Economy? Beyond the GLP-1 Boom GLP-1 drugs have put peptides on investors' radar, with Eli Lilly (LLY) and Novo Nordisk (NVO) leading the weight-loss market. But the investment opportunity extends beyond these treatments.
View source ↗ - Newsglobenewswire.com·31d ago·Negative
Fractyl Health Sharpens Focus on Revita Following Positive Pivotal Results, Advancing Toward Planned FDA De Novo Submission in Post-GLP-1 Weight Maintenance Following positive topline six-month REMAIN-1 pivotal results, Revita advancing toward planned FDA De Novo submission in late Q4 2026 and anticipated 12-month pivotal data readout in Q1 2027 Workforce reduction aligns organization behind Revita's near-term clinical and commercial opportunity Company discontinuing development of Rejuva candid…
View source ↗ - Newsnewsfilecorp.com·31d ago·Negative
…Across Its Needle-Free Line Four U.S.-made transdermal peptide patches, one manufacturer, one brand: BPC-157 on sale, 20,000 TA1 units in production, Tirzepatide and GLP3 in development Highlights Exclusive manufacturing rights secured for all four of the Company's patch formulations: BPC-157, Thymosin Alpha-1 (TA1), tirzepatide and GLP3 Four patches, one U.S. manufacturer, one brand: each patch produced solely for The Precision Peptide Company The Recovery Patch (BPC-157) is on sale now; 20,000…
View source ↗ - Newsaccessnewswire.com·32d ago·Neutral
Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule KELOWNA, BC / ACCESS Newswire / October 21, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, reports that full enrollment has been reached and dosing continues on schedule with Human Pilot Study #7 (GLP-1-H26-7) which is evaluating two oral DehydraTECH-semaglutide ("DHT-sema") compositions against Novo's® commercially available Wegov…
View source ↗ - Newszacks.com·32d ago·Negative
Bet on This New GLP-1 ETF to Gain Exposure to a Booming Market REX Shares recently launched the REX Peptide ETF (PEPT), a thematic fund offering global exposure to the peptide industry, from drug developers to manufacturers and delivery platforms.
View source ↗ - Newszacks.com·33d ago·Neutral
Global Partners (GLP) is an Incredible Growth Stock: 3 Reasons Why Global Partners (GLP) possesses solid growth attributes, which could help it handily outperform the market.
View source ↗ - Newsseekingalpha.com·34d ago·Neutral
Hims & Hers Health: The Lollapalooza Effect Of GLP-1s Hims & Hers Health (HIMS) is positioned as a dominant DTC Telehealth platform leveraging GLP-1s to create frictionless, sticky consumer habits. HIMS benefits from powerful psychological drivers—pain avoidance, reward optimization, envy, and social proof—fueling rapid ARPU growth and long-term retention. I model conservative revenue growth to $3.5B in 2026, scaling to strong operating margins, and derive a fair value of $104 per share (272% up…
View source ↗ - Newsglobenewswire.com·37d ago·Negative
Fractyl Health's Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study, With Highly Statistically Significant Reduction in Weight Regain After GLP-1 Discontinuation REMAIN-1 met its six-month co-primary endpoint with high statistical significance (p=0.0023; mITT population); demonstrated 80% retention of GLP-1 induced weight loss vs 67% for sham
View source ↗ - Newsaccessnewswire.com·38d ago·Negative
Lexaria Announces Results from Animal Study GLP-1-A26-1 Results highlighted by a 566% improvement in brain absorption of DehydraTECH-CBD KELOWNA, BC / ACCESS Newswire / October 15, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide the following results from animal study GLP-1-A26-1 (the "Study") that evaluated a number of formulation enhancements using both DehydraTECH-CBD ("DHT-CBD") compositions and …
View source ↗ - Newsaccessnewswire.com·39d ago·Neutral
DataMEDS Si Licenses U.S. Rights To Reboot Health AI's Direct-To-Consumer GLP-1 Weight Management Platform Platform to be integrated into Health Lives Here app as a subscription offering TAMPA, FL / ACCESS Newswire / October 14, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its super intelligence platform EinsteinRx™ and smart contracts platform PharmacyC…
View source ↗ - Newsmarketbeat.com·40d ago·Negative
Biomea Fusion's BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study Biomea Fusion NASDAQ: BMEA reported top-line results from a Phase Ib multiple ascending-dose study of BMF-650, an investigational oral small-molecule GLP-1 receptor agonist being developed for weight management. The company said the 28-day study showed weight reduction across active-treatment cohorts, while reported gastrointestinal adverse events were mild or moderate.
View source ↗ - Newsglobenewswire.com·40d ago·Negative
Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist SAN CARLOS, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company, today announced Phase 1 GLP-131 clinical trial results for BMF-650, its investigational oral small-molecule glucagon-like peptide-1 receptor agonist (“GLP-1 RA”), which demonstrated consistent weight reduct…
View source ↗ - Newsnewsfilecorp.com·40d ago·Negative
The Precision Peptide Company Advances Needle-Free GLP-1 Tirzepatide Patch into Formal U.S. Testing Milestone advances the Company's transdermal peptide patch expanding the Company's growing portfolio across oral, topical and needle-free wellness formats Highlights Formal U.S. testing now underway for the Company's needle-free tirzepatide GLP-1 transdermal patch Targets the US$66 billion global GLP-1 market, projected to reach US$185.3 billion by 2033²,³ Existing tirzepatide products delivered b…
View source ↗ - Newsglobenewswire.com·41d ago·Neutral
Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist Company to host conference call and webcast on October 13, 2026, at 4:30 p.m. ET (1:30 p.m. PT) Company to host conference call and webcast on October 13, 2026, at 4:30 p.m. ET (1:30 p.m. PT)
View source ↗ - Newsmarketwatch.com·45d ago·Negative
GLP-1s could offer unexpected relief from back and knee pain, but doctors urge caution Rapid weight loss can lead to issues with bone quality, particularly in older adults.
View source ↗ - Newsprnewswire.com·45d ago·Neutral
Victory Square Announces U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Platform Milestone advances portfolio company's intellectual-property foundation for InsuTab™ and BuccaGLP™, supported by an exclusive worldwide UBC licence and Hydreight's previously disclosed U.S. distribution rights VANCOUVER, BC, Oct. 8, 2026 /PRNewswire/ -- Victory Square Technologies Inc. ("Victory Square," "VST" or the "Company") (CSE: VST) (OTCQX: VSQTF) (FWB: 6F6) today announced…
View source ↗ - Newsprnewswire.com·45d ago·Neutral
Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology Milestone advances the technology behind Hydreight's strategic investment and previously announced U.S. distribution rights VANCOUVER, BC and LAS VEGAS, Oct. 8, 2026 /PRNewswire/ -- Hydreight Technologies Inc. ("Hydreight" or the "Company") (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6) today announced that Insu Therapeutics Inc. ("Insu"), in which Hydreight holds a strategic investment, h…
View source ↗ - Newsseekingalpha.com·46d ago·Positive
Eli Lilly: Buy The GLP-1 Growth Premium Eli Lilly is building a dominant obesity and diabetes treatment portfolio, positioning itself as a high-growth, premium-valued pharmaceutical company. LLY's tirzepatide-based products, Mounjaro and Zepbound, drive nearly $15 billion in revenue with 91% and 46% YoY growth, respectively. I assign a buy rating to LLY, justifying its 25x EV/EBITDA premium by 20%+ annual sales growth and robust free cash flow expansion.
View source ↗ - Newsprnewswire.com·46d ago·Neutral
FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body New approach proposes an alternative to repeated injections HOUSTON, Oct. 7, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, a…
View source ↗ - Newsfool.com·47d ago·Neutral
Novo Stock Is Down More Than 70% From Its Peak. Value Trap or Generational Buying Opportunity? Novo Nordisk rose dramatically because investors were excited after it launched the first GLP-1 weight-loss drug. The company lost the lead in the emerging GLP-1 space to Eli Lilly.
View source ↗ - Newsthenewswire.com·47d ago·Negative
GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications Oral GLP-1 market projected to expand from $5.1 billion in 2026 to $89 billion in 2034 Novo announces additional weight-loss in patients switching from injected to oral delivery
View source ↗ - Newscnbc.com·51d ago·Neutral
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes, either as independent treatments or layered on top of existing drugs. A new slate of injections, pills, and combination regimens target the amylin pathway, which involves a hormone released in the pancreas alongside insulin that helps regulate hunger and fullness.
View source ↗ - Newsglobenewswire.com·52d ago·Negative
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss In a predefined MRI substudy, trevogrumab prevented 70% of muscle loss associated with semaglutide treatment A pre-specified subgroup analysis found that patients meeting the low lean mass definition for sarcopenia had greater loss of lean mass with semaglutide, and more preservation with trevogrumab Findings were presented at the European Association for the Study of …
View source ↗ - Newsprnewswire.com·52d ago·Negative
Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease In post-hoc analyses of ATTAIN-1, Foundayo 17.2 mg was associated with a predicted 57% and 18% reduction in risk of type 2 diabetes and cardiovascular disease vs. placebo Combined with recent research on the savings tied to weight loss, these findings suggest Foundayo could help reduce long-term spending for patients and healthcare syst…
View source ↗ - Newsprnewswire.com·53d ago·Neutral
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study In ACHIEVE-4, participants taking Foundayo experienced a 16% lower risk of MACE-4 and a 23% lower risk of MACE-3, meeting the primary objective for non-inferiority compared to insulin glargine In pre-planned analyses, Foundayo showed a 53% lower risk of cardiovascular death and a 57% lower risk of all-cause death vs. in…
View source ↗ - Newsproactiveinvestors.com·54d ago·Negative
Solvonis says alcohol treatment outpaces GLP-1 drugs in cross-trial comparison Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF) says new analysis of its ketamine-based alcohol treatment shows patients cut heavy drinking days by 67% compared with placebo, more than four months after their last dose. The company says that puts SVN-001 ahead of naltrexone, sold as Vivitrol, and the GLP-1 drugs semaglutide and pemvidutide on the same measure.
View source ↗ - Newscnbc.com·58d ago·Neutral
Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s Novo this week laid out an ambitious strategy to reignite growth beyond its top-selling Wegovy and Ozempic injections, but faces an uphill battle to win back investors and obesity market share. Meanwhile, Lilly continues to chip away at the company's position in the market – including in the burgeoning obesity pill space.
View source ↗ - Newsfool.com·58d ago·Negative
Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy? Viking is testing weight loss drug candidates in late-stage trials. The company recently showed that weight loss lasts after taking its drug candidate.
View source ↗ - Newsetftrends.com·60d ago·Negative
NTHM ETF Rotates Into Midstream Energy & GLP-1 Healthcare The NBI Thematic Rotation ETF (NTHM:TSX) has completed its latest portfolio rebalance, pivoting away from broad tech and industrial momentum to channel capital into midstream energy infrastructure and GLP-1 weight-loss drug manufacturers. The fund tracks the Thematic Rotation Quality Momentum Screened Index (TRQMS).
View source ↗ - Newszacks.com·60d ago·Positive
Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1? NVO's rare disease pipeline gains momentum as Frehemgo and Sogroya receive positive CHMP opinions for EU approval, opening new growth opportunities beyond GLP-1.
View source ↗ - Newsproactiveinvestors.com·61d ago·Negative
GLP-1 maker Novo Nordisk's big reveal leaves the City cold Novo Nordisk (NYSE:NVO) pulled back the curtain on its future at an investor day in London, and the audience filed out distinctly underwhelmed. The Danish drugs giant, best known for the weight-loss sensation Wegovy, used its biennial capital markets day to explain how it will thrive once its blockbuster obesity drugs lose patent protection.
View source ↗ - Newsprnewswire.com·61d ago·Negative
Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens 22% Placebo-Adjusted Weight Loss Reported at Week 33 Following Weekly Dosing of VK2735 at 17.5 mg; No Plateau Observed Results Demonstrate Viability of Monthly and Every Other Week Dosing Regimens for Maintaining Weight Loss; Increasing Options for Adherence to Treatment Up to 97% of Weight Loss Maintained Following Transition…
View source ↗ - Newscnbc.com·62d ago·Negative
Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs Eli Lilly CEO Dave Ricks told CNBC on Monday that 700,000 new seniors have started GLP-1 treatments since Medicare coverage of obesity drugs launched in July. In an exclusive interview, Ricks said 70% of those patients are on Lilly medicines.
View source ↗ - Newscnbc.com·62d ago·Negative
Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
View source ↗ - Newsmarketbeat.com·63d ago·Neutral
WW International Eyes Cash Flow Turnaround as GLP-1 Care Gains Momentum WW International NASDAQ: WW executives outlined the company's efforts to reposition its weight-management business around behavioral support, telehealth and GLP-1 medications, following a restructuring that substantially reduced its debt burden.
View source ↗ - Newsyoutube.com·65d ago·Positive
40% of U.S. Adults to Use GLP-1s? Raul Shah on LLY, NVO & Weight Loss "Mania" Raul Shah (@Raul_DSF) is very bullish on the future of GLP-1s due to accelerating demand trends generating a "mania" effect in the market. He points to the superiority Eli Lilly (LLY) has demonstrated through earnings and weighs if Novo (NVO) has a chance to catch up.
View source ↗ - Newsseekingalpha.com·66d ago·Negative
Kailera Therapeutics: An Outside Biotech Bet For The Next GLP-1 Obesity Drug Approval Kailera Therapeutics, Inc. targets the high-potential GLP-1 obesity market, leveraging a $718M IPO and a robust pipeline licensed from Hengrui. KLRA's lead candidate, ribupatide, shows competitive mean weight loss (23.6% at 36 weeks) and a favorable safety profile in ex-China studies. Despite a 40% post-IPO share price drop, KLRA's $1.65 bn valuation appears attractive given its late-stage pipeline and $900m ca…
View source ↗ - Newsaccessnewswire.com·68d ago·Neutral
The GLP-1 Era Has a Trust Problem - AimwellBio is Building the Physician Network to Solve It Company plans to integrate telemedicine into its verified health intelligence platform and opens a ten-seat Founding Physician Cohort spanning GLP-1 and metabolic care, hormone and menopause health, and physician-directed therapies for men and women. MIAMI, FL / ACCESS Newswire / September 15, 2026 / Aimwell Partners Inc. (OTCID:AIMN), parent company of AimwellBio, today announced plans to integrate tele…
View source ↗ - Newsyoutube.com·72d ago·Neutral
Making Getting Skinny Taste Good: Cava CEO On The GLP-1 Boom From smaller portions and adults ordering kids meals to more protein and Mediterranean-style eating, Cava CEO Brett Schulman breaks down how GLP-1s are changing customer behavior. Check out our daily newsletter!
View source ↗ - Newszacks.com·72d ago·Neutral
Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s LLY's immunology portfolio is gaining ground, with steady revenue growth, pipeline expansion and acquisitions broadening its next wave.
View source ↗ - Newsbenzinga.com·74d ago·Positive
Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule MannKind Corporation (NASDAQ:MNKD) shares are trading lower on Wednesday as traders react to the company's entry into a licensing and collaboration deal tied to an inhaled, rapid-acting GLP-1 program.
View source ↗ - Newsglobenewswire.com·74d ago·Negative
Independent Model Estimates Up To $11,142 in Gross Medical Cost Savings Per Member Over Five Years for Omada's GLP-1 Program SAN FRANCISCO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit healthcare provider, announced a new, independent cost savings model that examined the measurable clinical and economic value of Omada's GLP-1 program.1 GlobalData , a data analytics and consulting company, recently published a report estimating greater disease r…
View source ↗ - Newszacks.com·81d ago·Neutral
3 Reasons Why Growth Investors Shouldn't Overlook Global Partners (GLP) Global Partners (GLP) could produce exceptional returns because of its solid growth attributes.
View source ↗ - Newsmarketbeat.com·81d ago·Neutral
Lilly's Merida Deal Shows the GLP-1 King Is Already Thinking Beyond Obesity Eli Lilly and Company TodayLLYEli Lilly and Company$1,171.40 +11.40 (+0.98%) As of 11:00 AM Eastern This is a fair market value price provided by Massive. Learn more.52-Week Range$712.05▼$1,292.65Dividend Yield0.59%P/E Ratio39.28Price Target$1,292.18Add to WatchlistOn Aug. 31, Eli Lilly & Co. NYSE: LLY announced its intention to acquire Merida Biosciences for $2.875 billion.
View source ↗ - Newsproactiveinvestors.co.uk·81d ago·Positive
Citi flags GLP-1 prescription slowdown at Novo Nordisk, reiterates 'sell' Citi has reiterated its 'sell' rating on Novo Nordisk (NYSE:NVO), the Danish pharmaceutical group, with a price target of 265 Danish krone against a last close of 292.4 Danish krone. Analyst Emmanuel Papadakis published Citi's weekly IQVIA tracker of Novo's GLP-1 assets, using retail prescription data up to 21 August 2026.
View source ↗ - Newsmarketbeat.com·82d ago·Negative
Fractyl Health Eyes 2028 Revita Launch for Post-GLP-1 Weight Maintenance Fractyl Health NASDAQ: GUTS outlined a commercial strategy for its investigational Revita procedure, positioning the one-time endoscopic therapy as a potential option for patients seeking to maintain weight loss after discontinuing GLP-1 medicines.
View source ↗ - Newsfool.com·82d ago·Neutral
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%? Amylyx Pharmaceuticals raised $500 million to strengthen its balance sheet. A potential 2027 drug launch could provide the company's next catalyst.
View source ↗ - News247wallst.com·82d ago·Negative
Jim Cramer: This Little-Talked-About Drug Could Target the “Biggest Market of All Time” Aside From Eli Lilly's GLP-1 Drugs Jim Cramer is flagging an Amgen drug that Wall Street has largely ignored, and he thinks the cardiovascular opportunity behind it could rival the most valuable pharmaceutical market ever created.
View source ↗ - Newsreuters.com·83d ago·Negative
GLP-1 weight loss drugs effective even at low starter doses People taking popular GLP-1 obesity drugs who remain on low starter doses will lose some weight but may still experience side effects, although significantly less nausea than those who graduate to higher manufacturer-recommended doses, a new study suggests.
View source ↗ - Newsreuters.com·83d ago·Negative
Hims & Hers offers GLP-1 weight-loss drugs, men's health treatments in Australia Telehealth company Hims & Hers said on Monday it has begun offering branded GLP-1 weight-loss drugs and other treatments to men in Australia as it continues to expand its international business.
View source ↗ - Newsfool.com·84d ago·Negative
Should Eli Lilly Investors Be Worried About a Threat From Amylyx? Eli Lilly generated nearly two-thirds of its sales from GLP-1 drugs in the second quarter of 2026. Amylyx is one of many competitors seeing success in developing new GLP-1 drugs.
View source ↗ - News247wallst.com·86d ago·Negative
GLP-1 Coverage Fell From 72% to 60%. Is Eli Lilly's Weight-Loss Boom Hitting an Insurance Wall? Employer insurance coverage for GLP-1 weight-loss drugs is shrinking, yet Eli Lilly just posted a 47% revenue surge. Something underneath the headlines is keeping volumes alive, and it changes how shareholders should read every coverage headline going forward.
View source ↗ - Newsbarrons.com·87d ago·Negative
Novo Nordisk Stock Is Downgraded to Sell, and GLP-1s Aren't the Reason Deutsche Bank downgrades Novo Nordisk, citing doubts over the drugmaker's ability to return to growth and navigate an impending patent cliff.
View source ↗ - Newsbusinesswire.com·89d ago·Neutral
IFF Report Finds GLP-1 Is Reshaping Food Choices and Eating Behaviors Among Indian Consumers NEW DELHI--(BUSINESS WIRE)--IFF (NYSE: IFF) — a global leader in flavors, fragrances and health and biosciences — released new research examining how GLP-1 use is influencing food behaviors among Indian consumers and what those shifts may mean for the future of food and beverage innovation. The study is the latest in IFF's GLP-1 global consumer insights following the company's 2025 GLP-1 Consumer Opportu…
View source ↗ - Newsproactiveinvestors.co.uk·90d ago·Neutral
Lilly's GLP-1 pill hits UK pharmacies as US battle with Novo intensifies Eli Lilly's weight-loss and diabetes pill goes on sale in UK pharmacies from Monday, giving patients an oral alternative to the injections that have dominated the market. Foundayo, also known as orforglipron, is available on private prescription after the Medicines and Healthcare products Regulatory Agency approved it earlier this month.
View source ↗ - Newsseekingalpha.com·93d ago·Neutral
Structure Therapeutics: A Strong Bet For An Oral GLP-1 Approval Before 2030 Structure Therapeutics (GPCR) maintains a Buy rating, driven by strong Phase 2b data for its oral GLP-1 candidate aleniglipron targeting obesity. Aleniglipron demonstrated up to 16.2% weight loss at 44 weeks, a favorable discontinuation rate, and is now in Phase 3 studies with pivotal data expected Q4 2028. GPCR's $1.34bn cash position is expected to fund completion of Phase 3, supporting a runway through key value infle…
View source ↗ - Newsfool.com·94d ago·Neutral
There's a Black Market for Eli Lilly's Unapproved GLP-1 Drug. Here's Why That's Bullish Eli Lilly's unapproved retatrutide is already popular, as evidenced by the black market for it. This underscores the strength of Eli Lilly's weight-loss pipeline.
View source ↗ - Newszacks.com·94d ago·Negative
Can Awiqli Help Novo Nordisk Build a New Growth Engine Beyond GLP-1s? NVO's U.S. launch of Awiqli introduces the first once-weekly basal insulin, potentially giving the company a new growth opportunity beyond its pressured GLP-1 franchise.
View source ↗ - Newsglobenewswire.com·94d ago·Positive
Fractyl Health to Host Virtual Commercial Strategy Day on Tuesday, September 1, 2026: The Potential Path to Commercializing Revita®, a Procedural Therapy for Post-GLP-1 Weight Maintenance BURLINGTON, Mass., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it will host a virtual Commercial Strategy Da…
View source ↗ - Newsinvezz.com·96d ago·Negative
Amylyx stock soars on GLP-1 success: here's why investors should sell Amylyx Pharmaceuticals (AMLX) shares exploded to the upside on August 18th after the company reported blockbuster topline results from its pivotal Phase 3 LUCIDITY trial. The late-stage study evaluated avexitide – the pharmaceutical firm's first-in-class GLP-1 receptor antagonist – in patients suffering from post-bariatric hypoglycemia (PBH).
View source ↗ - Newsbarrons.com·96d ago·Negative
Amylyx Stock Surges 21% After GLP-1 Drug Succeeds in Phase 3 Trial Amylyx Pharmaceuticals says its GLP-1 receptor antagonist, avexitide, met both the primary and secondary endpoints in a late-stage clinical trial.
View source ↗ - Newszacks.com·97d ago·Neutral
Is Global Partners (GLP) a Solid Growth Stock? 3 Reasons to Think "Yes" Global Partners (GLP) could produce exceptional returns because of its solid growth attributes.
View source ↗ - Newsfool.com·100d ago·Neutral
GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk) Amgen is developing a highly differentiated GLP-1 product. Regeneron has a pair of promising GLP-1 candidates in the pipeline.
View source ↗ - Newszacks.com·101d ago·Neutral
Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge? NVO's GLP-1 pills offer fresh momentum, but Eli Lilly's fast-growing injectable and oral therapies threaten to widen the competitive gap.
View source ↗ - Newsglobenewswire.com·102d ago·Negative
Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission Final histology and laboratory analyses support the study's safety and performance objectives THE WOODLANDS, TX, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the successful completion of its Good Laboratory Practice (GLP)
View source ↗ - Newsmarketbeat.com·103d ago·Negative
Apyx Medical Sees GLP-1 Boom Fueling Demand for Renuvion, AYON Body Contouring Apyx Medical NASDAQ: APYX is positioning its Renuvion technology and newly launched AYON Body Contouring System to address growing demand for surgical aesthetic procedures, a trend CEO Charlie Goodwin said has been reshaped by the increasing use of GLP-1 weight-loss drugs.
View source ↗ - Newsmarketbeat.com·103d ago·Neutral
Omada Health Touts Record Q2 as GLP-1 Demand Fuels Growth Strategy Omada Health NASDAQ: OMDA highlighted record second-quarter revenue and margin performance at the Canaccord Genuity Growth Conference, while outlining its strategy to expand across cardiometabolic conditions, deepen channel partnerships and use GLP-1-related demand to broaden customer relationships.
View source ↗ - Newszacks.com·104d ago·Positive
GLP Q2 Earnings Call Flags Hedging Costs Amid Strong Fuel Margins Global Partners flags higher hedged-inventory carrying costs from steep backwardation, even as strong fuel margins lifted second-quarter product margins.
View source ↗ - Newsfool.com·106d ago·Positive
Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics? Eli Lilly leads the GLP-1 market and could remain on top thanks to a deep pipeline. Viking Therapeutics' leading GLP-1 candidate looks very promising.
View source ↗
Earnings
Fri, Feb 26(in 3 months)
Consensus estimate $0.92 per share
Typical surprise -8.3% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Nov 6$1.26 vs $1.61miss
- Fri, Aug 7$1.86 vs $1.24beat
- Fri, May 8$1.85 vs $0.33beat
- Fri, Feb 27$0.54 vs $0.60miss
- Fri, Nov 7$0.66 vs $1.09miss
- Thu, Aug 7$0.55 vs $0.60miss
Estimates and results for GLP via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by GLP officers and directors.
- Bought
- $7.3m
- Sold
- $1.5m
31 trades
14 trades
- Global Gp Llcbought
- Global Gp Llcbought
- Global Gp Llcbought
- Global Gp Llcbought
- Global Gp Llcbought
- Global Gp Llcbought
- Global Gp Llcbought
- Global Gp Llcbought
55 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Mark E. Greenhouse · TN07 · disclosed Oct 18, 2021 (13d later)Sell$100,001 - $250,000
- Mark E. Greenhouse · TN07 · disclosed Oct 18, 2021 (12d later)Sell$250,001 - $500,000
- Mark E. Greenhouse · TN07 · disclosed Sep 30, 2021 (6d later)Buy$15,001 - $50,000
- Mark E. Greenhouse · TN07 · disclosed Sep 30, 2021 (7d later)Buy$15,001 - $50,000
- Mark E. Greenhouse · TN07 · disclosed Sep 23, 2021 (22d later)Buy$100,001 - $250,000
- Mark E. Greenhouse · TN07 · disclosed Sep 23, 2021 (21d later)Buy$100,001 - $250,000
- Mark E. Greenhouse · TN07 · disclosed May 10, 2021 (3d later)Sell$100,001 - $250,000
- Mark E. Greenhouse · TN07 · disclosed Apr 28, 2021 (13d later)Buy$100,001 - $250,000
- Mark E. Greenhouse · TN07 · disclosed Sep 16, 2020 (33d later)Sell$100,001 - $250,000
- Mark E. Greenhouse · TN07 · disclosed Aug 18, 2020 (7d later)Sell$50,001 - $100,000
- Mark E. Greenhouse · TN07 · disclosed Aug 12, 2020 (6d later)Buy$15,001 - $50,000
- Mark E. Greenhouse · TN07 · disclosed Aug 12, 2020 (8d later)Buy$1,001 - $15,000
- Mark E. Greenhouse · TN07 · disclosed Aug 12, 2020 (8d later)Buy$15,001 - $50,000
- Mark E. Greenhouse · TN07 · disclosed Jul 18, 2020 (16d later)Buy$15,001 - $50,000
- Mark E. Greenhouse · TN07 · disclosed Jul 6, 2020 (26d later)Buy$1,001 - $15,000
- Mark E. Greenhouse · TN07 · disclosed Jul 6, 2020 (26d later)Buy$50,001 - $100,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
